Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calceneurin drugs during acute liver allograft rejection

Transplantation

Volumn 77, Issue 12, 2004, Pages 1815-1820

  Boleslawski, Emmanuel ^a   Conti, Filomena ^a   Sanquer, Sylvia ^b   Podevin, Philippe ^a   Chouzenoux, Sandrine ^a   Batteux, Frédéric ^a   Houssin, Didier ^c   Weill, Bernard ^a   Calmus, Yvon ^a,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c Cochin Hospital ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALCINEURIN INHIBITOR; CD8 ANTIGEN; CYCLOSPORIN; INTERLEUKIN 2; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNE STATUS; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; CALCINEURIN; CD8-POSITIVE T-LYMPHOCYTES; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREDNISOLONE; REOPERATION; TACROLIMUS; TIME FACTORS;

EID: 3042651960     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000129914.75547.B3     Document Type: Article

References (31)

1. Lindholm A. Cyclosporine A clinical experience and therapeutic drug monitoring. Ther Drug Monit 1995; 17: 631.
2. Stein CM, Murray JJ, Wood AJJ. Inhibition of stimulated interleukin-2 production in whole blood: A practical measure of cyclosporine effect. Clin Chem 1999; 45: 1477.
3. Batiuk TD, Kung L, Halloran PF. Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J Clin Invest 1997; 100: 1894.
4. Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996; 80: 40.
5. Liu J, Farmer JDJ, Lane WS, et al. Calcineurin is a common target of immunophyllin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807.
6. Batiuk T, Pazderka F, Halloran P. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Transplantation 1995; 59: 1400.
7. Koutouby T, Zucker C, Zucker K, et al. Molecular monitoring of the immunosuppressive effects of cyclosporine in renal transplant patients by using a quantitative polymerase chain reaction. Human Immunol 1993; 36: 227.
8. Platz KP, Mueller AR, Rossaint R, et al. Cytokine pattern during rejection and infection after liver transplantation-improvements in postoperative monitoring? Transplantation 1996; 62: 1441.
9. van den Berg AP, Twilhaar WN, Mesander G, et al. Quantitation of immunosuppression by flow cytometric measurement of the capacity of T cells for interleukin-2 production. Transplantation 1998; 65: 1066.
10. Chen Y, McKenna GJ, Yoshida EM, et al. Assessment of immunologic status of liver transplant recipients by peripheral blood mononuclear cells in response to stimulation by donor alloantigen. Ann Surg 1999; 230: 242.
11. Enz A, Shapiro G, Chappuis A, et al. Nonradioactive assay for protein phophatase 2B (calcineurin) activity using a partial sequence of the subunit of cAMP-dependent protein kinase as substrate. Anal Biochem 1994; 216: 147.
12. Jason J, Larned J. Single-cell cytokine profiles in normal humans: comparison of flow cytometric reagents and stimulation protocols. J Immunol Methods 1997; 207: 13.
13. Klintmalm GB, Nery JR, Husberg BS, et al. Rejection in liver transplantation. Hepatology 1989; 10: 978.
14. Mor E, Gonwa TA, Husberg BS, et al. Late-onset acute rejection in orthotopic liver transplantation-associated risk factors and outcome. Transplantation 1992; 54: 821.
15. Cakaloglu Y, Tredger J, Devlin J, et al. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK-506 and cyclosporine in liver transplant recipients. Hepatology 1994; 20: 309.
16. Halloran PF, Helms LMH, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356.
17. Caruso R, Perico N, Cattaneo D, et al. Whole-blood calcineurin activity is not predicted by cyclosporin blood concentration in renal transplant recipients. Clin Chem 2001; 47: 1679.
18. Dallman M, Shiho O, Page T, et al. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med 1991; 173: 79.
19. Kutukculer N, Clark K, Rigg KM, et al. The value of posttransplant monitoring of interleukin (IL)-2, IL-3, IL-4, IL-6, IL-8, and soluble CD23 in the plasma of renal allograft recipients. Transplantation 1995; 59: 333.
20. Tilg H, Vogel W, Aulitzky WE, et al. Evaluation of cytokines and cytokine-induced secondary messages in sera of patients after liver transplantation. Transplantation 1990; 49: 1074.
21. Gorczynski RM, Adams RB, Levy GA, et al. Correlation of peripheral blood lymphocyte and intragraft cytokine mRNA expression with rejection in orthotopic liver transplantation. Surgery 1996; 120: 496.
22. Baan CC, van Emmerik NE, Balk AH, et al. Cytokine mRNA expression in endomyocardial biopsies during acute rejection from human heart transplants. Clin Exp Immunol 1994; 97: 293.
23. de Groot-Kruseman HA, Baan CC, Hagman EM, et al. Intragraft interleukin 2 mRNA expression during acute cellular rejection and left ventricular total wall thickness after heart transplantation. Heart 2002; 87: 363.
24. Rostaing L, Puyoo O, Tkaczuk J, et al. Differences in type 1 and type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs tacrolimus) in stable renal allograft recipients. Clin Transplant 1999; 13: 400.
25. Nashan B, Cole E, Levy GA, et al. Clinical validation studies of neoral C2 monitoring: a review. Transplantation 2002; 73: S3.
26. Levy GA, Burra P, Cavallari A, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on two-hour post dose level (C2). Transplantation 2002; 73: 953.
27. Le Moine A, Goldman M, Abramowicz D. Multiple pathways to allograft rejection. Transplantation 2002; 73: 1373.
28. Tannapfel A, Kohlhaw K, Ebelt J, et al. Apoptosis and the expression of Fas and Fas ligand (FasL) antigen in rejection and reinfection in liver allograft specimens. Transplantation 1999; 67: 1079.
29. Graubert TA, DiPersio JF, Russell JH, et al. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 1997; 100: 904.
30. Shresta S, Pham CT, Thomas DA, et al. How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 1998; 10: 581.
31. Ilano AL, McConnell MV, Gurley KE, et al. Cellular basis of allograft rejection in vivo. V. Examination of the mechanisms responsible for the differing efficacy of monoclonal antibody to CD4+ T cell subsets in low- and high-responder rat strains. J Immunol 1989; 143: 2828-36.